| BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study N Von Bubnoff, F Schneller, C Peschel, J Duyster The Lancet 359 (9305), 487-491, 2002 | 609 | 2002 |
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, ... Leukemia 29 (10), 2062-2068, 2015 | 590 | 2015 |
| Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease R Zeiser, N von Bubnoff, J Butler, M Mohty, D Niederwieser, R Or, J Szer, ... New England Journal of Medicine 382 (19), 1800-1810, 2020 | 554 | 2020 |
| Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ... The Lancet Oncology 19 (6), 747-757, 2018 | 547 | 2018 |
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease S Spoerl, NR Mathew, M Bscheider, A Schmitt-Graeff, S Chen, T Mueller, ... Blood, The Journal of the American Society of Hematology 123 (24), 3832-3842, 2014 | 427 | 2014 |
| Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development A Burchert, Y Wang, D Cai, N Von Bubnoff, P Paschka, ... Leukemia 19 (10), 1774-1782, 2005 | 272 | 2005 |
| Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells NR Mathew, F Baumgartner, L Braun, D O'Sullivan, S Thomas, ... Nature medicine 24 (3), 282-291, 2018 | 256 | 2018 |
| Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state J Den Hollander, S Rimpi, JR Doherty, M Rudelius, A Buck, A Hoellein, ... Blood, The Journal of the American Society of Hematology 116 (9), 1498-1505, 2010 | 250 | 2010 |
| Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) N Von Bubnoff, PW Manley, J Mestan, J Sanger, C Peschel, J Duyster Blood 108 (4), 1328-1333, 2006 | 207 | 2006 |
| Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms A Prestipino, AJ Emhardt, K Aumann, D O’Sullivan, SP Gorantla, ... Science translational medicine 10 (429), eaam7729, 2018 | 205 | 2018 |
| Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy RK Kancha, N Von Bubnoff, C Peschel, J Duyster Clinical cancer research 15 (2), 460-467, 2009 | 203 | 2009 |
| Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial PY Wen, A Stein, M van den Bent, J De Greve, A Wick, FYFL de Vos, ... The lancet oncology 23 (1), 53-64, 2022 | 202 | 2022 |
| Endothelial‐like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction I Ott, U Keller, M Knoedler, KS Götze, K Doss, P Fischer, K Urlbauer, ... The FASEB journal 19 (8), 992-994, 2005 | 163 | 2005 |
| Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back N Von Bubnoff, C Peschel, J Duyster Leukemia 17 (5), 829-838, 2003 | 157 | 2003 |
| Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers P Horak, C Heining, S Kreutzfeldt, B Hutter, A Mock, J Hüllein, M Fröhlich, ... Cancer discovery 11 (11), 2780-2795, 2021 | 153 | 2021 |
| A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor N Von Bubnoff, DR Veach, H Van Der Kuip, WE Aulitzky, J Sänger, ... Blood 105 (4), 1652-1659, 2005 | 141 | 2005 |
| Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib RK Kancha, N von Bubnoff, N Bartosch, C Peschel, RA Engh, J Duyster PloS one 6 (10), e26760, 2011 | 135 | 2011 |
| Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma C Dierks, J Seufert, K Aumann, J Ruf, C Klein, S Kiefer, M Rassner, ... Thyroid 31 (7), 1076-1085, 2021 | 125 | 2021 |
| International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study WR Sperr, M Kundi, I Alvarez-Twose, B van Anrooij, JNGO Elberink, ... The Lancet Haematology 6 (12), e638-e649, 2019 | 125 | 2019 |
| FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro N Von Bubnoff, RA Engh, E Aberg, J Sanger, C Peschel, J Duyster Cancer research 69 (7), 3032-3041, 2009 | 123 | 2009 |
